Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C28H30N6O3 |
Molecular Weight | 498.5762 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CNC1=CC(NC(=O)N[C@@H]2N=C(C3=NC=CC=C3)C4=CC=CC=C4N(CC(=O)C(C)(C)C)C2=O)=CC=C1
InChI
InChIKey=YDZYKNJZCVIKPP-VWLOTQADSA-N
InChI=1S/C28H30N6O3/c1-28(2,3)23(35)17-34-22-14-6-5-12-20(22)24(21-13-7-8-15-30-21)32-25(26(34)36)33-27(37)31-19-11-9-10-18(16-19)29-4/h5-16,25,29H,17H2,1-4H3,(H2,31,33,37)/t25-/m0/s1
Molecular Formula | C28H30N6O3 |
Molecular Weight | 498.5762 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Netazepide (YF476) is an orally active, benzodiazepine type, selective cholecystokinin B receptor (CCKBR; CCK2R; gastrin receptor) antagonist with potential gastric acid reducing and antiproliferative activity. Upon administration, netazepide, selectively binds to and blocks the CCKBR, thereby preventing the binding of gastrin and cholecystokinin. This may prevent gastric neuroendocrine enterochromaffin-like (ECL) cell-induced secretion of histamine, ultimately preventing gastric acid secretion from adjacent parietal cells. In addition, YF476 may inhibit ECL cell proliferation and ECL-derived gastric carcinoids. Netazepide has been used in trials studying the prevention and treatment of dyspepsia, hypergastrinaemia, barrett's esophagus, ECL-cell hyperplasia, and rebound hyperacidity, among others. Netazepide once daily for 12 weeks reduced the number of tumours and size of the largest one in 16 patients with autoimmune chronic atrophic gastritis (CAG), achlorhydria, hypergastrinaemia and multiple gastric neuroendocrine tumours (type 1 gastric NETs), and normalized circulating chromogranin A (CgA) produced by enterochromaffin-like cells, the source of the tumours.
Originator
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Effect of netazepide, a gastrin/CCK2 receptor antagonist, on gastric acid secretion and rabeprazole-induced hypergastrinaemia in healthy subjects. | 2015 May |
|
Netazepide, a gastrin/cholecystokinin-2 receptor antagonist, can eradicate gastric neuroendocrine tumours in patients with autoimmune chronic atrophic gastritis. | 2017 Mar |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23432534
Single oral doses of netazepide (1, 5, 25 and 100 mg)
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9042983
Netazepide (YF476) replaced the specific binding of [125I]CCK-8 to the rat brain, cloned canine and cloned human gastrin/CCK-B receptors, with Ki values of 0.068, 0.62 and 0.19 nM, respectively.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:16:17 GMT 2023
by
admin
on
Fri Dec 15 16:16:17 GMT 2023
|
Record UNII |
HOU4I0G29C
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C63817
Created by
admin on Fri Dec 15 16:16:17 GMT 2023 , Edited by admin on Fri Dec 15 16:16:17 GMT 2023
|
||
|
FDA ORPHAN DRUG |
243207
Created by
admin on Fri Dec 15 16:16:17 GMT 2023 , Edited by admin on Fri Dec 15 16:16:17 GMT 2023
|
||
|
EU-Orphan Drug |
EU/3/07/452
Created by
admin on Fri Dec 15 16:16:17 GMT 2023 , Edited by admin on Fri Dec 15 16:16:17 GMT 2023
|
||
|
NCI_THESAURUS |
C29701
Created by
admin on Fri Dec 15 16:16:17 GMT 2023 , Edited by admin on Fri Dec 15 16:16:17 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID00165906
Created by
admin on Fri Dec 15 16:16:17 GMT 2023 , Edited by admin on Fri Dec 15 16:16:17 GMT 2023
|
PRIMARY | |||
|
C104428
Created by
admin on Fri Dec 15 16:16:17 GMT 2023 , Edited by admin on Fri Dec 15 16:16:17 GMT 2023
|
PRIMARY | |||
|
8943
Created by
admin on Fri Dec 15 16:16:17 GMT 2023 , Edited by admin on Fri Dec 15 16:16:17 GMT 2023
|
PRIMARY | |||
|
DB12355
Created by
admin on Fri Dec 15 16:16:17 GMT 2023 , Edited by admin on Fri Dec 15 16:16:17 GMT 2023
|
PRIMARY | |||
|
CHEMBL324547
Created by
admin on Fri Dec 15 16:16:17 GMT 2023 , Edited by admin on Fri Dec 15 16:16:17 GMT 2023
|
PRIMARY | |||
|
HOU4I0G29C
Created by
admin on Fri Dec 15 16:16:17 GMT 2023 , Edited by admin on Fri Dec 15 16:16:17 GMT 2023
|
PRIMARY | |||
|
9870520
Created by
admin on Fri Dec 15 16:16:17 GMT 2023 , Edited by admin on Fri Dec 15 16:16:17 GMT 2023
|
PRIMARY | |||
|
155488-25-8
Created by
admin on Fri Dec 15 16:16:17 GMT 2023 , Edited by admin on Fri Dec 15 16:16:17 GMT 2023
|
PRIMARY | |||
|
100000183821
Created by
admin on Fri Dec 15 16:16:17 GMT 2023 , Edited by admin on Fri Dec 15 16:16:17 GMT 2023
|
PRIMARY | |||
|
C87692
Created by
admin on Fri Dec 15 16:16:17 GMT 2023 , Edited by admin on Fri Dec 15 16:16:17 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|